InsiderTrades

Form 4 for TYRA Tyra Biosciences, Inc.

Accepted 2021-09-17 00:00:00 ET · period of report 2021-09-17 · accession 0000899243-21-036431 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2021-09-17 2021-09-17 TYRA MORE ROBERT J Dir P - Purchase $16.00 +156.2K 4.08M +4% +$2.50M
DI 2021-09-17 2021-09-17 TYRA MORE ROBERT J Dir C - Cnv Deriv — +3.81M 3.92M +3,375% —
DMI 2021-09-17 2021-09-17 TYRA MORE ROBERT J Dir C - Cnv Deriv $0.00 -1.47M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-09-17 P A 156,250 $16.00 4,080,296 I See footnote — — (F2) These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.
2 Common Common Stock 2021-09-17 C A 3,811,117 — 3,924,046 I See footnote — — (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F2) These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.
3 Derivative Series A Preferred Stock 2021-09-17 C D 1,212,122 $0.00 0 I See footnote — · — to — 3,148,365 Common Stock (F2) These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
4 Derivative Series B Preferred Stock 2021-09-17 C D 255,160 $0.00 0 I See footnote — · — to — 662,752 Common Stock (F2) These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein. (F1) On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.